Whittier Trust’s TherapeuticsMD TXMD Stock Holding History

Whittier Trust’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2	Closed	–	–	1456
2019 Q1	$0	Buy	+2	New	+$529	﹤0.01%	1498

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Whittier Trust's TXMD Position: Q2 2019 in Review

Whittier Trust sold out of TherapeuticsMD (TXMD) in Q2 2019, closing a stake of 2 shares.

Whittier Trust first reported a position in TXMD in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

Whittier Trust reported no remaining TherapeuticsMD position as of Q2 2019 after selling out during the quarter.
Whittier Trust sold 2 TherapeuticsMD shares in Q2 2019.
Whittier Trust first reported a position in TherapeuticsMD in Q1 2019 and held it in 1 quarter.
Whittier Trust's TherapeuticsMD position peaked at $0 in Q1 2019.
148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on Whittier Trust's 13F filing for Q2 2019, filed 23 Jul 2019.